Pulseless ventricular tachycardia screening: Difference between revisions
Homa Najafi (talk | contribs) No edit summary |
Aisha Adigun (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Pulseless ventricular tachycardia}} | {{Pulseless ventricular tachycardia}} | ||
{{CMG}}; {{AE}}{{Aisha}} | {{CMG}}; {{AE}}{{Aisha}} {{ADG}} | ||
==Overview== | ==Overview== | ||
According to the 2017 American Heart Association guidelines screening of first-degree relatives is recommended when a patient presents with any of the symptoms such as [[Long QT syndrome|QT syndrome]], [[Hypertrophic cardiomyopathy|hypertrophic]] or [[dilated cardiomyopathy]] and right ventricular dysplasia. | |||
==Screening== | ==Screening== | ||
According to the 2017 American Heart Association /American College of Cardiology/Heart Rhythm Society guideline screening of first-degree relatives is recommended when a patient is identified as having any of the following:<ref name="pmid5731530">{{cite journal |vauthors=Shoubkhova TS |title=[Determination of the particle size of suspensions of dried bacteria by the method of turbidimetric analysis] |language=Russian |journal=Zh. Mikrobiol. Epidemiol. Immunobiol. |volume=45 |issue=7 |pages=108–10 |date=July 1968 |pmid=5731530 |doi= |url=}}</ref><ref name="pmid30554599">{{cite journal |vauthors=Flannery MD, La Gerche A |title=Sudden Death and Ventricular Arrhythmias in Athletes: Screening, De-Training and the Role of Catheter Ablation |journal=Heart Lung Circ |volume=28 |issue=1 |pages=155–163 |date=January 2019 |pmid=30554599 |doi=10.1016/j.hlc.2018.10.004 |url=}}</ref> | |||
*[[Long QT syndrome|QT syndrome]] | |||
*[[Hypertrophic cardiomyopathy|Hypertrophic]] or [[dilated cardiomyopathy]] | |||
*[[Right ventricular]] dysplasia | |||
==References== | ==References== | ||
Latest revision as of 11:41, 7 June 2020
|
Pulseless ventricular tachycardia Microchapters |
|
Differentiating Pulseless ventricular tachycardia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Pulseless ventricular tachycardia screening On the Web |
|
American Roentgen Ray Society Images of Pulseless ventricular tachycardia screening |
|
Risk calculators and risk factors for Pulseless ventricular tachycardia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aisha Adigun, B.Sc., M.D.[2] Aditya Ganti M.B.B.S. [3]
Overview
According to the 2017 American Heart Association guidelines screening of first-degree relatives is recommended when a patient presents with any of the symptoms such as QT syndrome, hypertrophic or dilated cardiomyopathy and right ventricular dysplasia.
Screening
According to the 2017 American Heart Association /American College of Cardiology/Heart Rhythm Society guideline screening of first-degree relatives is recommended when a patient is identified as having any of the following:[1][2]
- QT syndrome
- Hypertrophic or dilated cardiomyopathy
- Right ventricular dysplasia
References
- ↑ Shoubkhova TS (July 1968). "[Determination of the particle size of suspensions of dried bacteria by the method of turbidimetric analysis]". Zh. Mikrobiol. Epidemiol. Immunobiol. (in Russian). 45 (7): 108–10. PMID 5731530.
- ↑ Flannery MD, La Gerche A (January 2019). "Sudden Death and Ventricular Arrhythmias in Athletes: Screening, De-Training and the Role of Catheter Ablation". Heart Lung Circ. 28 (1): 155–163. doi:10.1016/j.hlc.2018.10.004. PMID 30554599.